Cargando…

Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey

Background: Previous research has shown different effects of hematological malignancies on the outcome of patients with COVID-19 infection depending on the type of disease and the treatment received. This research was aimed at examining the clinical outcome of COVID-19 infection in positive patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ćojbašić, Irena, Golubović, Ivana, Ćojbašić, Žarko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533142/
https://www.ncbi.nlm.nih.gov/pubmed/37763683
http://dx.doi.org/10.3390/medicina59091564
_version_ 1785112128000098304
author Ćojbašić, Irena
Golubović, Ivana
Ćojbašić, Žarko
author_facet Ćojbašić, Irena
Golubović, Ivana
Ćojbašić, Žarko
author_sort Ćojbašić, Irena
collection PubMed
description Background: Previous research has shown different effects of hematological malignancies on the outcome of patients with COVID-19 infection depending on the type of disease and the treatment received. This research was aimed at examining the clinical outcome of COVID-19 infection in positive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Methods: We collected retrospective information on chronic myeloid leukemia patients who were treated and monitored in our institution during the pandemic period. Within this cohort, we recorded COVID-19 positive symptomatic patients and analyzed their basic characteristics, symptoms, severity, and outcome. Results: In the study cohort when COVID-19 was diagnosed, 86.7% of patients were on first-generation tyrosine kinase inhibitors therapy—imatinib. At the time of infection, 70% of patients were in molecular remission, 23.4% in complete cytogenetic remission, and 3.3% in complete hematological response. Most patients had symptomatic disease. Within the analyzed group, 56.7% of patients had asymptomatic/mild COVID-19 infection, 23.3% of patients had moderate symptoms which did not require hospitalization, and 20% of patients had severe/critical symptoms that required admission to the intensive care unit. More than half of the patients interrupted treatment with tyrosine kinase inhibitors temporarily during COVID-19. There were no deaths due to COVID-19 infection. Conclusions: In compliance with other larger clinical studies, analysis of the clinical outcome of COVID-19 infection in patients with chronic myeloid leukemia on tyrosine kinase inhibitors therapy in this study showed that they do not have an increased risk for COVID-19 infection and that they have a mild course of the disease with recovery.
format Online
Article
Text
id pubmed-10533142
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105331422023-09-28 Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey Ćojbašić, Irena Golubović, Ivana Ćojbašić, Žarko Medicina (Kaunas) Article Background: Previous research has shown different effects of hematological malignancies on the outcome of patients with COVID-19 infection depending on the type of disease and the treatment received. This research was aimed at examining the clinical outcome of COVID-19 infection in positive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Methods: We collected retrospective information on chronic myeloid leukemia patients who were treated and monitored in our institution during the pandemic period. Within this cohort, we recorded COVID-19 positive symptomatic patients and analyzed their basic characteristics, symptoms, severity, and outcome. Results: In the study cohort when COVID-19 was diagnosed, 86.7% of patients were on first-generation tyrosine kinase inhibitors therapy—imatinib. At the time of infection, 70% of patients were in molecular remission, 23.4% in complete cytogenetic remission, and 3.3% in complete hematological response. Most patients had symptomatic disease. Within the analyzed group, 56.7% of patients had asymptomatic/mild COVID-19 infection, 23.3% of patients had moderate symptoms which did not require hospitalization, and 20% of patients had severe/critical symptoms that required admission to the intensive care unit. More than half of the patients interrupted treatment with tyrosine kinase inhibitors temporarily during COVID-19. There were no deaths due to COVID-19 infection. Conclusions: In compliance with other larger clinical studies, analysis of the clinical outcome of COVID-19 infection in patients with chronic myeloid leukemia on tyrosine kinase inhibitors therapy in this study showed that they do not have an increased risk for COVID-19 infection and that they have a mild course of the disease with recovery. MDPI 2023-08-28 /pmc/articles/PMC10533142/ /pubmed/37763683 http://dx.doi.org/10.3390/medicina59091564 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ćojbašić, Irena
Golubović, Ivana
Ćojbašić, Žarko
Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey
title Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey
title_full Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey
title_fullStr Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey
title_full_unstemmed Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey
title_short Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection—A Single Center Survey
title_sort clinical outcomes of patients with chronic myeloid leukemia and covid-19 infection—a single center survey
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533142/
https://www.ncbi.nlm.nih.gov/pubmed/37763683
http://dx.doi.org/10.3390/medicina59091564
work_keys_str_mv AT cojbasicirena clinicaloutcomesofpatientswithchronicmyeloidleukemiaandcovid19infectionasinglecentersurvey
AT golubovicivana clinicaloutcomesofpatientswithchronicmyeloidleukemiaandcovid19infectionasinglecentersurvey
AT cojbasiczarko clinicaloutcomesofpatientswithchronicmyeloidleukemiaandcovid19infectionasinglecentersurvey